ezh2 inhibition sensitizes brg1 egfr mutant lung tumours topoii inhibitors
non-small-cell lung cancer leading cause cancer-related death worldwide chemotherapies topoisomerase ii topoii inhibitor etoposide effectively reduce disease minority patients cancer therefore alternative drug targets including epigenetic enzymes consideration therapeutic intervention promising potential epigenetic target methyltransferase ezh2 context polycomb repressive complex prc2 well known tri-methylate histone h3 lysine h3k27me3 elicit gene silencing demonstrate ezh2 inhibition differential effects topoii inhibitor response non-small-cell lung cancers vitro vivo egfr brg1 mutations genetic biomarkers predict enhanced sensitivity topoii inhibitor response ezh2 inhibition brg1 loss-of-function mutant tumours respond ezh2 inhibition increased s phase anaphase bridging apoptosis topoii inhibitor sensitivity conversely egfr brg1 wild-type tumours upregulate brg1 response ezh2 inhibition ultimately become resistant topoii inhibitor egfr gain-of-function mutant tumours also sensitive dual ezh2 inhibition topoii inhibitor genetic antagonism egfr brg1 findings suggest opportunity precision medicine genetically complex disease non-small-cell lung cancer
